Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Skye Bioscience, Inc. (SKYE : NSDQ)

• Company Description    Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $1.86 Daily Weekly Monthly 20 Day Moving Average: 184,430 shares Shares Outstanding: 4.43 (millions) Market Capitalization: $8.24 (millions) Beta: 2.90 52 Week High: $39.92 52 Week Low: $1.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -56.34% -56.14% 12 Week -68.13% -68.81% Year To Date -68.99% -72.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11250 EL CAMINO REAL SUITE 100 - SAN DIEGO,CA 92130 USA ph: 858-410-0266 fax: - ir@skyebioscience.com https://skyebioscience.com

• General Corporate Information    Officers Punit Dhillon - Chief Executive Officer Paul Grayson - Chairman Deborah Charych - Director Andrew J. Schwab - Director Karen Smith - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 83086J309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 4.43 Most Recent Split Date: 8.00 (0.13:1) Beta: 2.90 Market Capitalization: $8.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.04 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 38.64% vs. Previous Quarter: 15.62% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -329.08 03/31/26 - -217.27 12/31/25 - -143.59 ROA 06/30/26 - -201.79 03/31/26 - -162.39 12/31/25 - -119.89 Current Ratio 06/30/26 - 0.95 03/31/26 - 1.78 12/31/25 - 3.30 Quick Ratio 06/30/26 - 0.95 03/31/26 - 1.78 12/31/25 - 3.30 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - -0.11 03/31/26 - 2.05 12/31/25 - 5.00 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©